Amarin Corp Plc (AMRN)

[HDGabor]

N-

I do not want to convince anybody ... feel free (anybody, not you only) to think:
- Hikma launched meanwhile infringement is not a question
- Hikma launched a different product than the one that was approved by the FDA
- etc.

My view is the same: the US market - legally - gone. Amarin - maybe - can do something with the price (or as authorized generic) but it does not worth an investment for me.

I am "waiting" for one thing only, the EU approval in 2021 and the "consequnce" (if any) ... but I think I will see "better" entry point before the EoY, mid-December than the current level.

Best,
G

btw ... my "advise" to sell - anything above 4.50 - looks like reasonable now